Expression of soluble HLA-G in multiple myeloma patients and patients with renal failure

Własiuk, Paulina; Steć, Anna; Piechnik, Agnieszka; Kamińska, Wioletta; Dmoszyńska, Anna; Książek, Andrzej; Giannopoulos, Krzysztof

doi:10.1016/j.leukres.2012.02.015

Cited by 10 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher levels of sHLA‐G in patients with renal failure might facilitate development of malignant diseases which may result in infection‐related complications . Patients with renal insufficiency without malignant disease showed higher levels of sHLA‐G . These findings point to an altered clearance of sHLA‐G due to impaired renal function which causes accumulation of sHLA‐G concentrations in the plasma.…”

Section: Discussionmentioning

confidence: 95%

“…Similarly, Creput et al correlated HLA‐G expression with a decreased number of AR episodes in combined liver–kidney transplantation. Higher levels of sHLA‐G in patients with renal failure might facilitate development of malignant diseases which may result in infection‐related complications . Patients with renal insufficiency without malignant disease showed higher levels of sHLA‐G .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association of HLA‐G promoter and 14‐bp insertion–deletion variants with acute allograft rejection and end‐stage renal disease

et al. 2013

View full text Add to dashboard Cite

The aim of this study was to investigate the HLA-G 14-bp insertion/deletion (I/D) polymorphism among end-stage renal disease (ESRD) patients. Cytomegalovirus (CMV) infection, acute allograft rejection (AR) and overall survival after renal transplantation was investigated in 300 ESRD patients and 302 age, sex and ethnicity-matched controls. Sequencing was performed to evaluate the impact of HLA-G promoter region single-nucleotide polymorphisms (SNPs) whereas semi-quantitative PCR method was used to determine the probable HLA-G expression pattern among ESRD and AR cases. Further, soluble human leukocyte antigen (HLA)-G (sHLA-G) expression levels were compared in AR vs non-AR cases in the light of HLA-G 14-bp I/D polymorphism. Increased risk was found for 14-bp D/D (deletion-DD) genotype and 14-bp D allele [DD: odds ratio (OR) = 1.46, 95% confidence interval (CI) = 1.03-2.06, P value = 0.0358; D: OR = 1.29, 95% CI = 1.03-1.62, P value = 0.0277], respectively for ESRD and CMV infection (DD: OR = 2.70, 95% CI = 1.45-5.05, P value = 0.0021; D: OR = 1.94, 95% CI = 1.22-3.08, P value = 0.0052). Nearly fourfold (OR = 3.62, 95%CI = 1.61-8.14, p = 0.0039) risk was observed for 14-bp I/I (insertion-II) genotype for AR. Survival analysis showed increased overall survival (OS) (AR or death) for 14-bp D/D genotype. HLA-G promoter region sequencing was carried out among 60 ESRD patients and 100 normal controls which showed increased risk for -964 G>A, -725 C>G/T and -486 A>C SNPs. -964 G>A and -725 C>G/T SNPs showed risk association for AR patients. High level of HLA-G transcripts was observed among non-AR patients. Further soluble HLA-G (sHLA-G) showed increased levels in ESRD patients (mean ± SEM; 62.16 ± 2.43 U/ml) as compared to controls (mean ± SEM; 21.06 ± 3.89 U/ml) (P = <0.0001). The 14-bp I/I, 14-bp I/D and 14-bp D/D genotypes showed significantly higher levels of sHLA-G among non-AR as compared to AR patients.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Association of HLA‐G promoter and 14‐bp insertion–deletion variants with acute allograft rejection and end‐stage renal disease

et al. 2013

View full text Add to dashboard Cite

show abstract

“…In human reproduction, low HLA-G expression has been associated with greater risk for recurrent pregnancy loss [4,5]. In allogenic transplantation, expression of soluble or membrane HLA-G has been correlated with lower allograft rejection risk [1,[6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

HLA-G haplotype structure shows good conservation between different populations and good correlation with high, normal and low soluble HLA-G expression

Cristofaro¹,

Moujally²,

Agnel³

et al. 2013

Human Immunology

View full text Add to dashboard Cite

“…Moreover, MM are transformed terminally maturated B-cells and as such expressed ILT2 in BM and blood. However, despite this ILT2 expression, there are discrepancies in the reports on the function of HLA-G on MM, ranging from "indicative of bad prognosis" [8] to "irrelevant to prognosis" [13,14]. This indicates that ILT2 expression is not sufficient to explain the data discrepancies observed for the function of HLA-G on B-cell malignancies.…”

Section: Differences In Ilt2 Expression and Function By Tumor Cellsmentioning

confidence: 93%

“…Other studies revealed either a low HLA-G expression on B-CLL cells in the majority of cases [10,11] or increased soluble HLA-G levels in B-CLL [12], B-non-Hodgkin lymphomas [12], and MM patients [13,14] without any clinical association. and ILT2.…”

Section: Second Situation: Hla-g Expression Is Of Irrelevant Prognosismentioning

confidence: 97%

A controversy on HLA-G and B-cell malignancies?

Carosella

Rebmann²

2016

J Immunother Appl

View full text Add to dashboard Cite

show abstract

Expression of soluble HLA-G in multiple myeloma patients and patients with renal failure

Cited by 10 publications

References 13 publications

Association of HLA‐G promoter and 14‐bp insertion–deletion variants with acute allograft rejection and end‐stage renal disease

Association of HLA‐G promoter and 14‐bp insertion–deletion variants with acute allograft rejection and end‐stage renal disease

HLA-G haplotype structure shows good conservation between different populations and good correlation with high, normal and low soluble HLA-G expression

A controversy on HLA-G and B-cell malignancies?

Contact Info

Product

Resources

About